Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03393975
Other study ID # 281102
Secondary ID 2017-000858-18TA
Status Completed
Phase Phase 3
First received
Last updated
Start date October 13, 2017
Est. completion date May 30, 2024

Study information

Verified date June 2024
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can occur. People who have TTP may bleed underneath the skin forming purple bruises or purpura, or from the surface of the skin. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them leading to lower than normal number of red blood cells. A lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in blood clotting, causes TTP. The enzyme breaks up another blood protein called von Willebrand factor that clumps together with platelets to form blood clots. Some people are born with this condition, others get the condition during their life. Many people who born with TTP experience frequent flareups that need to be treated right away. If not treated It can be fatal or cause lasting damage, such as brain damage or a stroke. BAX 930 is a medicine that replaces ADAMTS13 and can prevent or control TTP flareups, called TTP events. The main aim of this study is to compare the number of TTP events in people born with severe TTP when they treated with BAX 930 versus when they are treated with the standard treatment. Treatment will be given in 2 ways: - BAX 930 or standard treatment given to prevent TTP events from happening. - BAX 930 or standard treatment given to control an acute TTP event when it happens, according to the clinic's standard practice. Both BAX 930 and standard treatment are given slowly through a vein (infusion). At the first visit, the study doctor will check if you can participate in the study. If you are eligible and enter the study, you will follow an assigned schedule and either start with BAX 930 (Period 1) and then switch to standard treatment (Period 2) or start with standard treatment (Period 1) and then switch to BAX 930 (Period 2). Everyone will be treated with BAX 930 again for Period 3. Each Period will last approximately 6 months. If you enter the study to control an acute TTP event, you will follow a schedule receiving either BAX 930 or standard care to treat your acute TTP event. Once the acute TTP event has gotten better, you can decide to continue in the study and be given treatment to prevent TTP events from happening, following the schedule above. Another study's aim is to assess side effects from treatment with BAX 930 and standard treatment. To do that, the study doctor will ask you questions about your health at each study visit. The study doctors will also check how long BAX 930 stays in the blood of the participants, over time. They will do this from blood samples taken after participants receive their specific infusions of BAX 930. This will happen at different times during the study. 1 month after all treatment has been completed, participants will visit the clinic for a final check-up.


Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
BAX930
Participants in prophylaxis cohort will receive IV infusions of 40 IU/kg BAX 930 ORT during Period 1 and Period 2 and switch to BAX 930 SIN during Period 3 for six months once in a week or twice in a week. In On-demand cohort participants will receive daily IV dose of BAX-930.
Standard of care
Participants will receive Investigator-recommended Standard of care (SoC).

See more »

Sponsors (2)

Lead Sponsor Collaborator
Baxalta now part of Shire Takeda Development Center Americas, Inc.

Countries where clinical trial is conducted

United States,  Austria,  France,  Germany,  Italy,  Japan,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events Number of acute TTP events among participants receiving either BAX 930 or standard of care (SoC) prophylactically during the corresponding treatment periods will be assessed. Throughout the study period of approximately 70 months
Secondary Percentage of Acute Thrombotic Thrombocytopenic Purpura (TTP) Events Responding to BAX 930 Percentage of acute TTP events responding to BAX 930, is defined as not requiring the use of another a human disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13 (ADAMTS13)-containing agent. Throughout the study period of approximately 70 months
Secondary Time to Resolution of Acute TTP Events Time to resolution of acute TTP events following initiation of treatment with BAX 930 or SoC agent will be assessed. Throughout the study period of approximately 70 months
Secondary Number of Participants With Thrombocytopenia Thrombocytopenia is defined as a drop in platelet count greater than or equal to (>=) 25 percent (%) of baseline or a platelet count less than (<) 150,000/mcgL reported by treatment arm for the prophylactic cohort. Throughout the study period of approximately 70 months
Secondary Number of Participants With Microangiopathic Hemolytic Anemia Microangiopathic hemolytic anemia is defined as an elevation of LDH greater than (>) 1.5* of baseline or >1.5* upper limit of normal (ULN) will be reported by treatment arm for the prophylactic cohort. Throughout the study period of approximately 70 months
Secondary Number of Participants With Neurological symptoms Neurological symptoms includes (e.g., confusion, dysphonia, dysarthria, focal or general motor symptoms including seizures will be reported by treatment arm for the prophylactic cohort. Throughout the study period of approximately 70 months
Secondary Number of Participants With Renal Dysfunction Renal dysfunction is defined as an increase in serum creatinine >1.5*baseline. Number of participants with renal dysfunction will be reported by treatment arm for the prophylactic cohort. Throughout the study period of approximately 70 months
Secondary Number of Participants With Abdominal Pain Number of participants with abdominal pain (TTP related) will be reported by treatment arm for the prophylactic cohort. Throughout the study period of approximately 70 months
Secondary Number of Participants With Supplemental Doses Number of participants with supplemental doses prompted by subacute TTP events will be reported by treatment for the prophylactic cohort. Throughout the study period of approximately 70 months
Secondary Number of Participants With Dose Modification Number of participants with dose modification not prompted by an acute TTP event will be reported by treatment for the prophylactic cohort. Throughout the study period of approximately 70 months
Secondary Number of Participants With Acute Thrombotic Thrombocytopenic Purpura (TTP) Events on Their Final Dose Number of participants with acute TTP events on their final dose and dosing regimen for the prophylactic cohort will be reported. Throughout the study period of approximately 70 months
Secondary Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) An AE is defined as any untoward medical occurrence in a participants administered an IP that does not necessarily have a causal relationship with the treatment. A SAE is defined as an untoward medical occurrence that at any dose meets 1 or more of the following criteria: death; initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly, medically important event (may not be immediately lifethreatening or result in death or require hospitalization but may require medical or surgical intervention to prevent 1 of the other outcomes: intensive treatment, confirmed seroconversion for human immunodeficiency viruses (HIV), severe hypersensitivity/allergic reactions, uncomplicated pregnancies etc). Vital signs, clinical chemistry, hematology will be assessed and reported as AE. Throughout the study period of approximately 70 months
Secondary Number of Participants With Antibodies to ADAMTS13 Number of participants with binding and inhibitory antibodies to ADAMTS13 will be reported. Throughout the study period of approximately 70 months
Secondary Estimated Total Quantity of ADAMTS13 Administered During the Treatment of Acute TTP Events Estimated total quantity of ADAMTS13 administered during the treatment of acute TTP events will be assessed. Acute TTP events typically require 3-4 days of intensified treatment. Throughout the study period of approximately 70 months
Secondary Incremental Recovery (IR) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma ADAMTS13 activity will be measured by the fluorescent resonance energy transfer (FRETS) assay, ADAMTS13 antigen will be measured using a commercial ADAMTS13 enzyme-linked immunosorbent assay (ELISA) employing ADAMTS13 antigen. IR is defined as body weight normalized maximum increase in plasma ADAMTS13 antigen and activity level. IR of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be assessed. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Area Under the Plasma curve [AUC] of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma AUC of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Terminal Half-Life (T1/2) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma T1/2 of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Mean Residence Time (MRT) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma MRT of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Clearance (CL) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma CL of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Volume at Steady State (Vss) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma Vss of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Maximum Concentration (Cmax) of ADMATS13 Activity and ADMATS13 Antigen for SoC Agent and BAX 930 in Plasma Cmax of ADMATS13 activity and ADMATS13 antigen for SoC agent and BAX 930 in plasma will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Assessment of Von Willebrand Factor: Antigen (VWF:Ag) VWF:Ag is a measure of total VWF protein and will be assessed using a sandwich ELISA employing polyclonal anti-human-VWF antibodies. Assessments of VWF:Ag at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Assessment of Von Willebrand Factor: Ristocetin Cofactor Activity (VWF: RCo) VWF:RCo will provide a measure of the ability of VWF to bind platelet glycoprotein Ib. Stabilized platelets are agglutinated in the presence of VWF and the antibiotic Ristocetin. Assessments of VWF:RCo at baseline and following infusion of the SoC agent and BAX 930 treatment during the initial PK assessment will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Assessment of ADAMTS13 Activity (Pre-Infusion ADAMTS13 Levels) and Select VWF Parameters Assessment of ADAMTS13 activity (pre-infusion ADAMTS13 levels) and select VWF parameters prior to each PK infusion of SoC or BAX 930 will be reported. Start of treatment periods and end of Treatment Period 2 prophylactic cohort. <12 years: within 60 min pre-infusion; and post-infusion at 6 timepoints up to 7 days. >=12 years: within 60 min pre-infusion; and post-infusion at 10 timepoints up to 12 days
Secondary Assessment of Total Binding Antibodies to ADAMTS13 Total binding antibodies to ADAMTS13 will be measured by an ELISA-based assay, detecting total immunoglobulins (IgG, IgA, and IgM). Assessment of total antibodies at baseline, start of each treatment periods and at study completion/early termination will be reported. Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Secondary Assessment of Neutralizing Antibodies to ADAMTS13 Neutralizing antibodies will be measured by a Bethesda method with Nijmegen modification using the ADAMTS13 FRETS-VWF73 activity assay. Assessment of neutralizing antibodies at baseline, start of each treatment periods and at study completion/early termination will be reported. Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Secondary Assessment of Anti-Chinese Hamster Ovary (Anti-CHO) Protein Antibodies Total immunoglobulin antibodies (Immunoglobulin G [IgG], A [IgA], and M [IgM]) against CHO protein will be analyzed using ELISA assay. Anti-CHO protein at baseline, start of each treatment periods and at study completion/early termination will be reported. Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Secondary Time to Onset of Immunogenic Response to ADAMTS13 Immunogenic response will assessed with the presence of total binding antibodies. Absence of total binding antibodies to ADAMTS13 is an indication of the absence of neutralizing (activity inhibition) antibodies to ADAMTS13. Time to onset of immunogenic response will be reported Start of treatment periods 1, 2 and 3: within 60 min pre-infusion and at study completion/early termination visit (up to 19 months)
Secondary Health Related Quality of Life (HRQoL): cTTP-Specific Patient reported outcomes (PROs) The congenital thrombotic thrombocytopenic purpura (cTTP)-specific patient-reported outcomes (PRO) instrument consists of 26 questions designed to assess the patient's experience of fatigue, joint, muscle, abdominal and chest pain in the previous 24 hours, neurologic manifestations, bruising, feelings of depression and mood alterations, and activity limitation in the past 7 days, and patient's attitudes, experienced side effects, work/school absences and travel impact associated with treatment received for TTP during the previous 2 weeks. The cTTP PRO assessment is focused on measuring the symptoms and impacts of the disease. The scores range from 0 to 152. Higher scores indicate a better quality of life. Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Secondary Health Related Quality of Life (HRQoL): 36-Item Short Form Health Survey (SF-36) The SF-36 is a generic quality-of-life instrument that has been widely used to assess health-related quality of life (HRQoL) of participants. Generic instruments are used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. The SF-36 consists of 36 items that are aggregated into 8 multi-item scales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health), with scores ranging from 0 to 100. Higher scores indicate better HRQoL. Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Secondary Health Related Quality of Life (HRQoL): Abbreviated 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9) TSQM is a global satisfaction scale used to assess the overall level of participant's satisfaction or dissatisfaction with their medications. TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness, convenience, and global satisfaction. The score of each of the 3 domains is based on an algorithm to create a score of 0 to 100. Higher score indicated greater satisfaction in that domain. Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Secondary Health Related Quality of Life (HRQoL): EuroQol 5 Dimensions Questionnaire 3-Level (EQ-5D-3L) EQ-5D-3L health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Secondary Health Related Quality of Life (HRQoL): EQ-5D-youth (EQ-5D-Y) EQ-5D-Y health questionnaire is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Secondary Health Related Quality of Life (HRQoL): Pediatric Quality of Life Inventory (Ped QL) The Peds QL is a generic health related quality of life instrument designed specifically for a pediatric population and captures following domains: physical functioning, emotional functioning, social functioning, school functioning, psychosocial summary, physical health and total score. The Peds-QL total score consist of all 23 items of all domains. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate better quality of life. Day 0, End of period 1 (approximately 6 months), End of period 2 (approximately 12 months), and End of period 3 (approximately 19 months), or non-scheduled acute event (as needed)
Secondary Resource Utilization: Length of Hospital Stay for Acute TTP Events Number of days participants stay in hospital for Acute TTP events will be assessed. Throughout the study period of approximately 70 months
Secondary Resource Utilization: Resource Utilization During Prophylaxis Number of participants utilized during prophylaxis will be assessed. Throughout the study period of approximately 70 months
Secondary Resource Utilization: Days Missed From School or Work due to TTP-Related Illness Number of days missed from school or work due to TTP-related illness will be assessed. Throughout the study period of approximately 70 months
See also
  Status Clinical Trial Phase
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Not yet recruiting NCT06441578 - A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Terminated NCT00411801 - Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) Phase 3
Recruiting NCT05714969 - A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Phase 2
Completed NCT00937131 - The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP) Phase 2
Recruiting NCT04683003 - A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Phase 3
Available NCT05770219 - Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)